Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Gilead and Other HIV Treatment-Making Companies Face Class Action Lawsuit

Gilead Sciences has been accused of withholding safer formulations of its HIV drugs in order to maximize profits on those medications that had already been approved, such as Truvada.

Read More »

J&J to submit NDAs for at least 10 new drugs by 2023

Johnson & Johnson expects to file marketing applications for at least 10 new drugs between 2019 to 2023, to strengthen the company’s pharma unit which has been a major growth driver.

Read More »

Mallinckrodt Completes Enrollment of Phase 3 Terlipressin CONFIRM Trial

Mallinckrodt plc announced that the company achieved target enrollment of 300 participants in the Phase 3 CONFIRM clinical study to evaluate the efficacy and safety of the investigational agent terlipressin in adult patients with Hepatorenal Syndrome Type 1 (HRS-1).

Read More »

Alnylam’s RNAi Therapy for Acute Hepatic Porphyria Positive in Phase III

Cambridge, Mass.-based Alnylam Pharmaceuticals indicated that the company’s ENVISION Phase III trial of givosiran was positive for acute hepatic porphyria (AHP).

Read More »

Top 10 Pipelines To Watch: 2019 Annual Report

The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.

Read More »

After Announcing a New CEO, UroGen Touts Positive Phase III Data for Urothelial Cancer

UroGen Pharma announced positive top-line results from the New York based-company’s Phase III OLYMPUS clinical trial that evaluated UGN-101 (mitomycin gel) for instillation for the non-surgical treatment of low-grade upper tract urothelial cancer.

Read More »

Kala Pharmaceuticals’s NDA for KPI-121 0.25% for Dry Eye Disease Accepted for FDA Review

Kala Pharmaceuticals Inc. announced that the New Drug Application (NDA) for KPI-121 0.25%, a product candidate for the temporary relief of signs and symptoms of dry eye disease utilizing a two-week course of therapy, has been accepted for review by the United States Food and Drug Administration FDA.

Read More »

BioSpace Readers’ Picks: Top 10 Stories of 2018

Here is a look at BioSpace’s top 10 stories of 2018.

Read More »

Esperion’s Bemopedoic Acid Treatments Hit the Mark in Two Studies

Ann Arbor, Mich.-based Esperion Therapeutics reported final results from a long-term safety study of bempedoic acid 180 mg versus placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) whose disease is inadequately controlled by statins.

Read More »

Alnylam’s gene silencing drug wins FDA approval

Alnylam Pharmaceuticals’ Onpattro won U.S. regulatory approval for a rare hereditary disease, becoming the first approved treatment from a new class of medicines that use gene silencing technology.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom